Regeneron Pharmaceuticals is looking into adding treatments for cardiovascular problems, diabetes, asthma and allergy to its pipeline, chief executive Leonard Schleifer revealed in an interview. Experimental drugs for diabetes, asthma and allergy are already in preclinical trials, and the company will develop two to three new medicines every year as part of its $872 million drug development deal with Sanofi-Aventis SA.

Full Story:

Related Summaries